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As potential treatments for C9ORF72-associated amyo-
trophic lateral sclerosis (c9ALS) approach clinical trials,
the identification of prognostic biomarkers for c9ALS
becomes a priority. We show that levels of phosphory-
lated neurofilament heavy chain (pNFH) in cerebrospinal
fluid (CSF) predict disease status and survival in c9ALS
patients, and are largely stable over time. Moreover,
c9ALS patients exhibit higher pNFH levels, more rapid
disease progression, and shorter survival after disease
onset than ALS patients without C9ORF72 expansions.
These data support the use of CSF pNFH as a prognos-
tic biomarker for clinical trials, which will increase the
likelihood of successfully developing a treatment for
c9ALS.
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Despite more than 50 large clinical trials in the pasthalf-century, there is only 1 minimally effective
treatment for amyotrophic lateral sclerosis (ALS), a dev-
astating motor neuron disease. Nevertheless, since the
discovery of C9ORF72 G4C2 repeat expansions as the
most common genetic cause of ALS,1,2 significant advan-
ces have been made toward elucidating the mechanisms
by which this mutation causes C9ORF72-associated ALS
(c9ALS), and devising therapeutic strategies to combat
them. Multiple lines of evidence place G4C2 repeat RNA
and dipeptide repeat (DPR) proteins synthesized from
these transcripts at the crux of c9ALS. Therapeutic strate-
gies that target G4C2 RNA, such as antisense oligonu-
cleotides (ASOs) and small molecules, reduce DPR pro-
tein levels, and mitigate other abnormalities caused by
G4C2 transcripts in c9ALS models.
3–6
As therapeutics for c9ALS are sought, we must
address barriers in moving a treatment from bench to
bedside, such as the lack of biomarkers to forecast disease
progression and confirm target engagement in clinical tri-
als. We recently established poly(GP) DPR proteins as a
promising pharmacodynamic biomarker for G4C2 RNA-
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targeting ASOs (c9ASOs),6 but forthcoming clinical trials
for c9ASOs will also benefit from biomarkers that pre-
dict disease course. Phosphorylated neurofilament heavy
chain (pNFH) and neurofilament light chain, which are
released into the interstitial fluid during axonal injury
and neurodegeneration, have emerged as putative prog-
nostic biomarkers.7 Levels of pNFH are elevated in cere-
brospinal fluid (CSF) and blood from patients with
ALS,8–14 and some studies show that pNFH levels are
associated with survival and/or indicators of disease pro-
gression.8,9,11–13,15 The prognostic potential of pNFH,
however, has yet to be specifically evaluated in c9ALS
patients, a population that differs clinically and patho-
physiologically from ALS patients without a C9ORF72
repeat expansion.16–19 We thus investigated pNFH as an
urgently needed prognostic biomarker for c9ALS.
Subjects and Methods
Participants
An international sampling of CSF from C9ORF72 expansion car-
riers (n5 135) and noncarriers with no known ALS- or fronto-
temporal dementia (FTD)-linked mutation (n5 107) was used.
Samples were obtained from asymptomatic C9ORF72 expansion
carriers, healthy individuals, and clinically symptomatic patients
diagnosed with ALS, ALS with comorbid FTD (ALS-FTD), or
FTD (Table). ALS patients met El Escorial criteria for this diag-
nosis.20 Diagnosis of FTD was obtained through established
guidelines21–24 and supported by neuropsychological testing and,
in autopsied patients, by pathologically verified frontotemporal
lobar degeneration. Our cohort comprised a collection of existing
samples from multiple biobanks and included samples collected
specifically for studies on neurofilaments. Longitudinally col-
lected CSF was available from 37 C9ORF72 expansion carriers
and 17 noncarriers. Written informed consent was obtained from
all participants or their legal next of kin if they were unable to
give written consent, and biological samples were obtained with
ethics committee approval.
Sample Collection
The standard operating procedures for the collection, process-
ing, and storage of CSF were generally consistent among sites.
In brief, CSF was collected in polypropylene tubes by lumbar
puncture (LP) and immediately placed on ice. With the excep-
tion of samples from 3 groups, the CSF was spun at low speed
at 48C within 30 minutes of collection to pellet any cellular
debris. Samples were aliquoted before storing at 2808C.
pNFH Analysis
The previously described Meso Scale Discovery immunoassay
used for this study employs a mouse antihuman pNFH anti-
body and a sulfo-tagged polyclonal anti-pNFH antibody as the
capture and detection antibodies, respectively, and a purified
bovine pNFH calibrator.25 The assay has been analytically
validated as a laboratory-developed test in the Iron Horse Clini-
cal Laboratory Improvement Amendments–certified laboratory.
Samples tested in duplicate have a coefficient of var-
iation< 10%. The intra- and interday precision of the assay is
also <10%. Reagents and quality control samples were trans-
ferred to Mayo Clinic Jacksonville, where all CSF samples were
tested at an 8-fold dilution, to establish commutability between
the two sites.
Statistical Analysis
ALS patient functional status was determined using the Amyo-
trophic Lateral Sclerosis Functional Rating Scale–Revised
(ALSFRS-R). For cross-sectional studies, the disease progression
score was calculated using the equation: (48 2 ALSFRS-R score
at baseline)/disease duration in months from disease onset to
baseline LP.8 For longitudinal studies, we used: (48 2
ALSFRS-R score at last LP)/disease duration in months from
disease onset to last LP.
Comparisons of pNFH levels across disease groups, and
associations of pNFH with disease progression score or survival
since disease onset, were conducted separately for C9ORF72
expansion carriers and noncarriers, as described below. Our pri-
mary analyses also included comparing pNFH levels, disease
progression scores, and survival after disease onset between
C9ORF72 expansion carriers and noncarriers. Given our 9 pri-
mary analyses, a Bonferroni adjustment was made and
p 0.0056 was considered statistically significant.
For regression analyses, pNFH values were log-scaled,
and a square root transformation was applied to the disease
progression scores due to their skewed distributions.
pNFH levels were compared among disease groups
(asymptomatic/healthy, ALS/ALS-FTD, FTD) using multivari-
ate linear regression (MLR) models adjusted for age at LP and
gender. Given a statistically significant (p 0.0056) difference
among groups, post hoc pairwise comparisons were made, with
p 0.0167 considered significant after Bonferroni correction.
The ability of pNFH to discriminate between disease groups
was examined by estimating the area under the receiver operat-
ing characteristic (ROC) curve.
Associations of pNFH levels in ALS/ALS-FTD patients
with disease progression scores were evaluated using MLR mod-
els adjusted for age at disease onset, gender, and onset site.
Additional adjustment for disease group (ALS or ALS-FTD)
was made only in C9ORF72 mutation carriers, as only 2 non-
carriers had ALS-FTD.
Associations of pNFH levels in ALS/ALS-FTD patients
with survival after disease onset were examined using multivariate
Cox proportional hazards regression models. Hazard ratios (HRs)
and 95% confidence intervals (CIs) were estimated, and censor-
ing occurred at the date of last follow-up. The multivariate model
for C9ORF72 mutation carriers was adjusted for age at disease
onset, gender, disease group, and onset site. For non–mutation
carriers, we adjusted only for age at disease onset and onset site
due to the smaller number of deaths in this subgroup.26 We addi-
tionally estimated the concordance index (c-index) with and with-
out pNFH in a given Cox model to provide an alternative mea-
sure of the predictive ability of pNFH; a c-index of 0.5 indicates
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predictive ability equal to that obtained by chance, and a c-index
of 1.0 indicates perfect predictive ability.
Comparisons of pNFH between ALS patients with a
C9ORF72 mutation and those without were made using MLR
models adjusted for age at LP, gender, onset to LP, and onset
site. Disease progression scores were compared using MLR
models adjusted for age at disease onset, gender, and onset site.
Comparisons of survival after disease onset were made using
multivariate Cox regression models adjusted for age at disease
onset, gender, and onset site.
For our secondary analyses, p 0.05 was considered sta-
tistically significant. The association of pNFH with poly(GP)
levels in C9ORF72 repeat expansion carriers, the latter mea-
sured as part of a recently published study,6 was examined using
a linear regression model. We also evaluated whether pNFH
levels change over time in subjects with longitudinally collected
CSF. The slope from a linear regression model (where pNFH
was the response and time after the baseline pNFH measure
was the predictor variable) was calculated separately for each
patient, and these slopes were tested for difference from a value
of zero (indicating no change in pNFH levels over time) using
a 1-sample t test.
All statistical tests were 2-sided, and analyses were per-
formed using SAS (v9.2; SAS Institute, Cary, NC) and R Statis-
tical Software (v2.14.0; R Foundation for Statistical Comput-
ing, Vienna, Austria).
Results
Evaluating CSF pNFH in C9ORF72
Mutation Carriers
To investigate the prognostic utility of pNFH in c9ALS
patients with or without comorbid FTD, the prevalence
of which is increased in C9ORF72 expansion car-
riers,16,17 we evaluated associations between pNFH levels
and disease status, progression, and survival after disease
onset using CSF from 86 c9ALS patients (14 with
comorbid FTD [c9ALS-FTD]) and 28 asymptomatic
individuals. Included for comparison was CSF from 21
c9FTD patients (see Table).
Compared to asymptomatic C9ORF72 expansion
carriers, CSF pNFH levels were higher in patients with
c9ALS/c9ALS-FTD (p< 0.0001) or c9FTD (p5 0.0004;
see Fig 1A). pNFH levels discriminated between c9ALS/
c9ALS-FTD patients and asymptomatic individuals with
an almost perfect area under the ROC curve of 0.996
(95% CI5 0.989–1.000). A cutoff value of 176pg/ml pro-
duced a sensitivity of 98.8% and a specificity of 96.4%
(see Fig 1B). In addition, pNFH levels were higher in
c9ALS/c9ALS-FTD compared to c9FTD (p< 0.0001),
with pNFH levels discriminating between c9ALS/c9ALS-
FTD patients and c9FTD patients with an area under the
ROC curve of 0.899 (95% CI5 0.808–0.990).
In c9ALS/c9ALS-FTD patients, there was a positive
correlation between pNFH levels and disease progression
score calculated using the ALSFRS-R (p5 0.012, n5 63;
see Fig 1C), but this did not reach statistical significance
(set at p 0.0056) after correction for multiple testing.
Survival data were available for 81 of the 86 c9ALS/
c9ALS-FTD patients; the median length of follow-up after
disease onset was 3.3 years (range5 1.0–11.7 years), and
59 patients (72.8%) died. A strong association was
observed between higher pNFH levels and shorter survival
after disease onset (HR [per each doubling of
pNFH]5 2.16, 95% CI5 1.47–3.16, p< 0.0001; see Fig
1D). Further illustrating the ability of pNFH levels to pre-
dict survival after disease onset, the model c-index was
0.66 when adjusting for age at disease onset, gender, dis-
ease group, and onset site; it improved to 0.72 when
pNFH was additionally included in the model.
Evaluating CSF pNFH in Non–C9ORF72
Mutation Carriers
We examined the same associations as above in individu-
als without a C9ORF72 mutation: 37 healthy subjects,
45 ALS patients (2 with comorbid FTD), and 25 FTD
patients (see Table).
CSF pNFH levels were significantly higher in ALS/
ALS-FTD patients compared to healthy individuals or
FTD patients (p< 0.0001; see Fig 1E), but not signifi-
cantly different between FTD patients and controls
(p5 0.054). pNFH levels discriminated between ALS/
ALS-FTD patients and healthy individuals with an area
under the ROC curve of 0.926 (95% CI5 0.861–
0.991); a cutoff value of 245pg/ml produced a sensitivity
of 89.0% and a specificity of 100.0% (see Fig 1F).
pNFH levels discriminated between ALS/ALS-FTD
patients and FTD patients with an area under the ROC
curve of 0.867 (95% CI5 0.776–0.957).
pNFH levels in ALS/ALS-FTD patients did not
associate with disease progression score (p5 0.12,
n5 36; see Fig 1G).
Survival data were available for 40 of the 45 ALS/
ALS-FTD patients; the median length of follow-up after
disease onset was 5.0 years (range5 1.4–20.0 years), and
18 patients (45.0%) died. A strong association was
observed between higher pNFH levels and shorter sur-
vival after disease onset (HR [per each doubling in
pNFH]5 3.04, 95% CI5 1.58–6.59, p5 0.002; see Fig
1H). Again demonstrating the ability of pNFH to pre-
dict survival after disease onset, the model that was
adjusted for only age at disease onset and onset site had
a c-index of 0.61, which increased to 0.77 when pNFH
was also included in the model.
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c9ALS Patients Exhibit Higher pNFH Levels
and Disease Progression Scores, and Shorter
Survival, Compared to ALS Patients without
a C9ORF72 Expansion
We next compared indicators of disease progression between
ALS patients with and without C9ORF72 expansions (see
Fig 1I, J and K). Given the increased prevalence of FTD in
ALS patients with a C9ORF72 expansion (14 of 86 patients
[16.3%]) versus those without (2 of 45 patients [4.4%]),
ALS-FTD patients were omitted from these analyses.
CSF pNFH levels (p< 0.0001) and disease pro-
gression scores (p5 0.003) were significantly higher in
FIGURE 1
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c9ALS patients compared to patients without the expan-
sion. Similarly, there was strong evidence of shorter sur-
vival after disease onset for patients with c9ALS com-
pared to those without the expansion (HR5 4.08, 95%
CI5 2.24–7.43, p< 0.0001).
We recently reported that CSF poly(GP) levels,
although a promising pharmacodynamic biomarker, do
not associate with survival after disease onset in c9ALS/
c9ALS-FTD.6 Consistent with these findings, poly(GP)
levels did not associate with pNFH levels (p5 0.21; see
Fig 1L).
Longitudinal pNFH Measurements
Longitudinally collected CSF was available from 37
C9ORF72 expansion carriers and 17 noncarriers. The
median length of time between the first and last pNFH
measurement was 12.9 months (range5 4.4–22.6 months)
and 5.8 months (range5 3.0–6.7 months) for C9ORF72
expansion carriers and noncarriers, respectively. There was
no evidence of a change in CSF pNFH levels over time in
C9ORF72 expansion carriers (p5 0.75), and the rate of
change in CSF pNFH did not differ between asymptom-
atic individuals and patients with c9ALS or c9ALS-FTD
(p5 0.83; Fig 2A). A similar lack of change in CSF pNFH
over time was observed in ALS patients without a
C9ORF72 expansion (p5 0.80; see Fig 2B). There was no
significant difference in the rate of change in CSF pNFH
between faster and slower progressors in patients with a
C9ORF72 expansion (p5 0.33), without an expansion
(p5 0.16), or combined (p5 0.094).
Discussion
Clinical trials for ALS are hampered by the lack of bio-
markers to monitor target engagement and predict dis-
ease course. The latter frequently results in clinical trial
treatment groups with significantly different proportions
of fast and slow progressors, thereby greatly increasing
the number of patients needed to detect a treatment
effect. With therapeutics for c9ALS being intensely inves-
tigated, and clinical trials for c9ASOs approaching, we
evaluated pNFH as a prognostic biomarker for c9ALS to
overcome this barrier.
Our study revealed a strong association between
higher CSF pNFH levels and shorter survival in ALS
patients with or without a C9ORF72 expansion, which is
consistent with previous reports.9,13 Given that the clini-
cal course of disease can vary substantially—one study
reports survival ranges of 0 to 7 years for c9ALS, and 3
to 38 years for ALS16—the ability of pNFH levels to
predict survival could facilitate the assessment of treat-
ment on prolonging life, and be used to stratify patients
into more homogenous groups to improve clinical trial
efficiency and the estimation of treatment outcomes.
We also noted a positive correlation between
pNFH levels and disease progression score in c9ALS and
c9ALS-FTD patients, but this was not significant after
adjustment for multiple testing, perhaps because of lower
power due to missing data for some patients, or a lack of
precision in the disease progression score, which depends
on a functional rating that is subject to bias.
That ALS patients with C9ORF72 expansions had
significantly higher pNFH levels than patients without
FIGURE 1: Evaluation of cerebrospinal fluid (CSF) phosphorylated neurofilament heavy chain (pNFH) in C9ORF72 repeat expan-
sion carriers and noncarriers. (A–H) pNFH levels were measured in CSF from individuals with a C9ORF72 repeat expansion (A–
D) and those without an expansion (E–H). (A) Scatter plot showing that CSF pNFH levels were higher in patients with
C9ORF72-associated amyotrophic lateral sclerosis with or without comorbid frontotemporal dementia (c9ALS6FTD, n586),
or patients with c9FTD (n521), compared to asymptomatic C9ORF72 repeat expansion carriers (c9ASX, n528). Patients with
c9ALS-FTD are represented by green circles. (B) Receiver operating characteristic (ROC) curves showing the ability of CSF
pNFH levels to discriminate between patients with c9ALS or c9ALS-FTD (n586) and either asymptomatic C9ORF72 repeat
expansion carriers (n528) or patients with c9FTD (n521). AUC5 area under the curve. (C) Association of CSF pNFH levels
and disease progression scores in patients with c9ALS or c9ALS-FTD (n563). (D) Survival after disease onset according to CSF
pNFH levels for c9ALS and c9ALS-FTD patients (n581). For ease of presentation, pNFH levels were divided into a 3-level cate-
gorical variable based on sample tertiles (Low £ 1.0980ng/ml, Moderate51.0981–1.6860ng/ml, High>1.6860ng/ml). (E) Scat-
ter plot showing that CSF pNFH levels among individuals without a C9ORF72 repeat expansion were higher in ALS patients
with or without comorbid FTD (n545) compared to healthy individuals (n537) or patients with FTD (n525). Patients with
ALS-FTD are represented by green circles. (F) ROC curves showing the ability of CSF pNFH levels to discriminate between
patients with ALS or ALS-FTD (n545) and either healthy individuals (n537) or patients with FTD (n525) without a C9ORF72
expansion. (G) CSF pNFH levels did not associate with disease progression scores in patients with C9ORF72-negative ALS or
ALS-FTD (n536). (H) Survival after disease onset according to CSF pNFH levels for ALS and ALS-FTD patients without a
C9ORF72 expansion (n540). For presentation purposes, pNFH levels were divided into a 3-level categorical variable based on
sample tertiles (Low £ 0.4660ng/ml, Moderate50.4661–1.0540ng/ml, High>1.0540ng/ml). (I) Comparison of CSF pNFH levels
between patients with c9ALS (n572) and C9ORF72-negative ALS (n543). (J) Comparison of disease progression scores
between patients with c9ALS (n554) and C9ORF72-negative ALS (n536). (K) Comparison of survival after disease onset
between patients with c9ALS (n568) and C9ORF72-negative ALS (n538). (L) CSF pNFH levels did not associate with CSF
poly(GP) levels in patients with c9ALS or c9ALS-FTD (n586). Straight lines in panels A, E, I, and J represent the median.
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this mutation presumably reflects increased neuronal
injury. c9ALS patients develop greater brain atrophy, par-
ticularly in extramotor regions, compared to ALS patients
without a C9ORF72 expansion.17,18 This diffuse spread
of degeneration may account for the more rapid disease
progression and shorter survival of c9ALS patients, as
observed herein and by others.16–19
We show that CSF pNFH levels are largely stable
over time. These findings from our relatively large cohort
of ALS patients are consistent with those from a study
examining 11 ALS patients longitudinally.9 This stability
of pNFH could facilitate its use as a pharmacodynamic
biomarker for drugs that mitigate axonal injury and neu-
rodegeneration. Additional longitudinal studies spanning
FIGURE 2: Longitudinal evaluation of cerebrospinal fluid (CSF) phosphorylated neurofilament heavy chain (pNFH) in C9ORF72
repeat expansion carriers and noncarriers. pNFH levels were measured in CSF collected longitudinally from C9ORF72 repeat
expansion carriers and noncarriers. Subjects are color-coded based on their disease progression score, with patients having a
score higher than the median (0.54 and 0.45 for C9ORF72 expansion carriers and noncarriers, respectively) considered faster
progressors, whereas those with a score equal to or lower than the median are considered slower progressors. (A) Among the
expansion carriers, 10 were asymptomatic, 20 were patients with C9ORF72-associated amyotrophic lateral sclerosis (c9ALS),
and 7 were patients with c9ALS and comorbid frontotemporal dementia. For these 37 subjects, the median length of time
between the first and last pNFH measurement was 12.9 months (range54.4–22.6 months); 25 subjects had 2 measurements,
9 subjects had 3 measurements, 2 subjects had 4 measurements, and 1 subject had 5 measurements. (B) For the 17 ALS
patients without a C9ORF72 expansion, the median length of time between the first and last pNFH measurement was 5.8
months (range53.0–6.7 months), and CSF pNFH was measured either 2 times (n52) or 3 times (n515).
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asymptomatic and symptomatic phases of disease would
be useful in determining at what point pNFH levels
begin to rise—information that could inform when best
to initiate treatment.
Overall, we established the prognostic potential of
CSF pNFH for c9ALS. These findings, together with
our discovery of a pharmacodynamic biomarker for
G4C2 RNA-targeting therapies,
6 will increase the likeli-
hood of successfully developing a treatment for c9ALS.
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TABLE Patient Characteristics according to C9ORF72 Repeat Expansion Status and Disease Group
C9ORF72 Repeat Expansion Carriers Non-C9ORF72 Repeat Expansion Carriers
Characteristic Asymptomatic,
n5 28
c9ALS or
c9ALS-FTD,
n5 86
c9FTD,
n5 21
Healthy,
n5 37
ALS or
ALS-FTD,
n5 45
FTD,
n5 25
Age at LP, yr 43 (28, 63) 59 (36, 76) 63 (45, 77) 60 (23, 85) 60 (26, 90) 67 (59, 84)
Age at disease onset, yr N/A 57 (34, 74) 61 (44, 76) N/A 57 (25, 87) 65 (39, 80)
Gender, male 8 [28.6%] 53 [61.6%] 11 [52.4%] 13 [35.1%] 30 [66.7%] 17 [68.0%]
Disease onset to LP, mo N/A 23 (0, 132) 47 (0, 103) N/A 27 (6, 204) 51 (6, 243)
Onset site
Bulbar N/A 28 [33.7%] N/A N/A 10 [23.3%] N/A
Limb N/A 51 [61.4%] N/A N/A 31 [72.1%] N/A
Other N/A 4 [4.8%] N/A N/A 2 [4.7%] N/A
ALSFRS-R score N/A 36 (7, 46) N/A N/A 37 (19, 45) N/A
Disease progression score N/A 0.5 (0.0, 2.8) N/A N/A 0.3 (0.1, 1.5) N/A
pNFH level, pg/ml 89 (35, 459) 1,406 (117, 4,671) 238 (86, 2,848) 100 (45, 209) 621 (50, 3,119) 181 (61, 502)
The sample median (minimum, maximum) is given for continuous variables. Information was unavailable for some subjects regarding age at LP
(n5 1 c9ALS, n5 1 ALS, n5 1 FTD), age at disease onset (n5 1 c9FTD), disease onset to LP (n5 1 c9FTD, n5 1 FTD), onset site (n5 1
c9ALS, n5 2 c9ALS-FTD, n5 2 ALS-FTD), ALSFRS-R score (n5 17 c9ALS, n5 5 c9ALS-FTD, n5 7 ALS, n5 2 ALS-FTD), and disease pro-
gression score (n5 18 c9ALS, n5 5 c9ALS-FTD, n5 7 ALS, n5 2 ALS-FTD). CSF samples were collected at the following institutions: Emory
University School of Medicine, National Institutes of Health, Mayo Clinic Jacksonville, University of Miami, IRCCS Istituto Auxologico Italiano,
University of Milan, Maggiore Hospital (Crema), Massachusetts General Hospital, University of Massachusetts Medical School, Barrow Neurologi-
cal Institute, University of Pittsburgh Medical Center, University of Pennsylvania, Washington University School of Medicine, and University Hos-
pital Mutua de Terrassa.
ALS5 amyotrophic lateral sclerosis; ALSFRS-R5Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised; c95C9ORF72-associated;
FTD5 frontotemporal dementia; LP5 lumbar puncture; N/A5 not applicable; pNFH5 phosphorylated neurofilament heavy chain.
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